3 "These new data could represent positive ... Paola Casarosa, Board of Managing Directors, Head of Innovation Unit at Boehringer Ingelheim, said: “Zongertinib’s efficacy and tolerability ...

1-3 Vision loss associated ... which in turn can have an impact on mental health, leading to depression, fear and anxiety.4 About Boehringer Ingelheim Boehringer Ingelheim is working on ...

At the IASLC 2024 World Conference on Lung Cancer (WCLC) Boehringer Ingelheim will present encouraging ... on Saturday, September 7, from 3:45PM to 4:45PM PDT (Location: 30DE).

Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record | ...

Boehringer Ingelheim’s weight-loss drug candidate ... dysfunction-associated steatotic liver disease (MASLD), which in turn has been rebranded from non-alcoholic fatty liver disease (NAFLD).

One strong late stage clinical study data readout for a GLP-1 agonist could turn a $1bn market cap ... and the latter's by over 400%. Boehringer Ingelheim and partner Zealand Pharma have a ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast. Boehringer Ingelheim reported this week that its phase 3 Fibroneer-IPF trial had met ...